一个关于晚期直肠癌患者的完整病理反应的案例研究,该患者接受了基于oxaliplatin的化疗,没有累积的神经毒性
Rehab A M Jawad1,2, Bahir Abdul-Razzaq Mshimesh3, Qasim S Al-Mayah4
1Department of Pharmacology and Toxicology, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq. rehab.ph@yahoo.com.
Journal of gastrointestinal cancer
|April 16, 2025
概括
一名直肠癌患者在没有化学辐射疗法的情况下,完全响应了oxaliplatin化疗,这可能是由于GSTP1遗传变异. 这突出了针对个性化癌症治疗和毒性降低的分子分析.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 结直肠癌治疗反应提供了对驱动瘤行为和治疗耐药性的分子机制的见解.
- 了解这些机制是改善治疗策略的关键.
研究的目的:
- 报告一个完全病理反应的病例在第三阶段的直肠癌治疗以酸为基础的化疗.
- 调查影响治疗反应和氧沙诱导的神经毒性的潜在遗传因素.
主要方法:
- 一个34岁的男性患有第三阶段直肠癌的案例研究.
- 治疗涉及基于oxaliplatin的化疗,而不是化疗或放射治疗.
- 进行了基因组分析,以确定相关的遗传变异,特别是GSTP1基因.
主要成果:
- 患者获得了完全的病理反应oxaliplatin化疗.
- 尽管氧沙的累积剂量高 (1700 mg/m2),但没有观察到神经毒性.
- 在GSTP1基因中确定了一种异合体 (Ile/Val) 基因型,可能与有利的治疗结果有关.
结论:
- 遗传生物标志物,如GSTP1基因型,可以指导治疗决策,潜在地允许患者避免放射治疗及其相关毒性.
- 分子分析有助于预测化学疗法诱导的神经毒性的易感性,使个性化剂量调整成为可能.
- 通过分子分析优化治疗策略可以提高患者的治疗结果和生活质量,特别是当放射性评估是模两可的时.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...